About statera biopharma inc - STAB
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.
STAB At a Glance
Statera Biopharma, Inc.
2580 East Harmony Road
Fort Collins, Colorado 80528
| Phone | 1-888-613-8802 | Revenue | 1.49M | |
| Industry | Biotechnology | Net Income | -101,850,817.00 | |
| Sector | Health Technology | 2021 Sales Growth | 465.538% | |
| Fiscal Year-end | 12 / 2022 | Employees | 16 | |
| View SEC Filings |
STAB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 54.305 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.203 |
| Enterprise Value to Sales | 63.951 |
| Total Debt to Enterprise Value | 0.171 |
STAB Efficiency
| Revenue/Employee | 92,939.75 |
| Income Per Employee | -6,365,676.063 |
| Receivables Turnover | 4.264 |
| Total Asset Turnover | 0.127 |
STAB Liquidity
| Current Ratio | 0.314 |
| Quick Ratio | 0.314 |
| Cash Ratio | 0.176 |
STAB Profitability
| Gross Margin | 49.975 |
| Operating Margin | -2,013.599 |
| Pretax Margin | -6,850.888 |
| Net Margin | -6,849.25 |
| Return on Assets | -867.269 |
| Return on Equity | N/A |
| Return on Total Capital | -693.188 |
| Return on Invested Capital | -2,950.895 |
STAB Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 110.672 |
| Total Debt to Total Assets | 76.813 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 77.799 |